CellBion Co., Ltd.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.cellbion.co.kr
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Phase 1
Active, not recruiting
- Conditions
- mCRPCProstate Cancer
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Cellbion Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT05547061
- Locations
- 🇰🇷
Chonnam National University Hwasun Hospital, Hwasun, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath